Source: International Congress 2017 – Clinical impact of nontuberculous mycobacterial (NTM) disease



Rating:

Share or cite this content

Citations should be made in the following way:
Won-Jung Koh (Seoul, Republic of Korea). The natural history of untreated NTM lung disease: a global perspective. International Congress 2017 – Clinical impact of nontuberculous mycobacterial (NTM) disease

Member's Comments

No comment yet.

Related content which might interest you: The global perspective of occupational lung disease Source: Eur Respir Monogr 2020; 89: 1-18 Year: 2020 The coexistence of asthma and COPD: risk factors, clinical history and lung function trajectories Source: Eur Respir J, 58 (5) 2004656; 10.1183/13993003.04656-2020 Year: 2021 The global burden of pulmonary disease: where we are and where we are going Source: International Congress 2019 – The future of respiratory diseases: what prevention can do Year: 2019 COPD as a lung disease with heterogeneous systemic inflammatory consequences: clinical impact Source: Research Seminar 2011 - Physical activity, nutritional status and systemic inflammation in COPD Year: 2011 Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course Source: Eur Respir J , 49 (3) 1600537; DOI: 10.1183/13993003.00537-2016 Year: 2017 When is an infectious disease? The clinical spectrum of nontuberculous mycobacterial pulmonary disease Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Year: 2019 Beyond pulmonary nontuberculous mycobacteria disease: do extra-pulmonary forms represent an emerging clinical and public health threat? Source: ERJ Open Res, 3 (3) 00091-2017; 10.1183/23120541.00091-2017 Year: 2017 Complexity in chronic asthma and COPD: implications for risk assessment, disease progression and control Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium Year: 2008 Lung cancer: the global burden of the disease Source: International Congress 2015 – Lung cancer screening: how to implement a comprehensive preventive approach Year: 2015 When should I suspect NTM disease? Source: ERS Course 2015 Year: 2015 Amyloid-and nonamyloid-deposition disease in the lung: novel manifestations Source: Annual Congress 2013 –Ceremony for ERS Award for Rare Pulmonary Disease (financially supported by GlaxoSmithKline) followed by Symposium: Autoimmunity and lung diseases in humans Year: 2013 A pathogen in patients with underlying lung disease: corynebacterium pseudodiphtericum Source: Annual Congress 2008 - Features of hospital-acquired pneumonia, ventilator-associated pneumonia and infection with other pathogens Year: 2008 How to assess the natural history of COPD? Source: Annual Congress 2013 –Natural history of COPD: novel aspects Year: 2013 Natural variability in the disease course of SSc-ILD: implications for treatment Source: Eur Respir Rev, 30 (159) 200340; 10.1183/16000617.0340-2020 Year: 2021 Smoking-related lung diseases: a clinical perspective Source: Eur Respir J 2010; 35: 231-233 Year: 2010 The clinical-radiological profile of pulmonary tuberculosis in young women from a community with a high burden of disease Source: Eur Respir J 2004; 24: Suppl. 48, 51s Year: 2004